Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Bibliographic Details
Main Authors:	Benjamin A. Derman, Andrew T. Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda K. Jasielec, Andrzej J. Jakubowiak
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-02-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-021-00418-2

Similar Items

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-09-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01)

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
by: Concetta Conticello, et al.
Published: (2019-06-01)

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
by: Meletios Dimopoulos, et al.
Published: (2018-04-01)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
by: Ja Min Byun, et al.
Published: (2020-05-01)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
by: Mohamad Mohty, et al.
Published: (2020-05-01)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
by: Noemi Puig, et al.
Published: (2021-05-01)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
by: Graham H Jackson, et al.
Published: (2021-01-01)

Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
by: Shuo Li, et al.
Published: (2018-01-01)

FDA approves ixazomib in combination with lenalidomide and dexamethasone for multiple myeloma
by: - -
Published: (2015-12-01)

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: D.S. Siegel, et al.
Published: (2020-11-01)

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
by: M. Turgut, et al.
Published: (2020-10-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
by: A. Maiolino, et al.
Published: (2020-11-01)

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES
by: H. Quach, et al.
Published: (2020-11-01)

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
by: Jiri Minarik, et al.
Published: (2021-01-01)

Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study
by: Justin Kline, et al.
Published: (2020-06-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
by: S. A. Tuchman, et al.
Published: (2012-01-01)

Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
by: Susana Aceituno, et al.
Published: (2018-06-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

The role of carfilzomib in relapsed/refractory multiple myeloma
by: Andrew J. Yee
Published: (2021-06-01)

Efficacy of Lenalidomide plus Low-Dose Dexamethasone in Thai Patients with Relapsed and/or Refractory Multiple Myeloma
by: Chutima Kunacheewa, et al.
Published: (2021-04-01)

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
by: Patrizia Tosi
Published: (2013-06-01)

Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India
by: Nithin Sashidharan, et al.
Published: (2015-05-01)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
by: Marc-Andrea Baertsch, et al.
Published: (2021-01-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
by: Steiner RE, et al.
Published: (2017-02-01)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar D, et al.
Published: (2015-01-01)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
by: Jenny Z. Yang, et al.
Published: (2021-09-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
by: Anderson, L.D., Jr, et al.
Published: (2022)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

A case of scleromyxedema responding to lenalidomide and dexamethasone
by: Sweta Rambhia, et al.
Published: (2017-01-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
by: Jacob P. Laubach, et al.
Published: (2021-02-01)

Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib
by: Vladimir Liberman, et al.
Published: (2016-07-01)